Lisata Therapeutics (NASDAQ:LSTA – Get Rating) and Ontrak (NASDAQ:OTRK – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.
Profitability
This table compares Lisata Therapeutics and Ontrak's net margins, return on equity and return on assets.
Get Lisata Therapeutics alerts:| Net Margins | Return on Equity | Return on Assets | |
| Lisata Therapeutics | N/A | -29.53% | -27.96% |
| Ontrak | -279.90% | -183.58% | -92.71% |
Valuation & Earnings
This table compares Lisata Therapeutics and Ontrak's gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lisata Therapeutics | N/A | N/A | -$27.47 million | ($12.23) | -0.30 |
| Ontrak | $84.13 million | 0.26 | -$37.14 million | ($3.38) | -0.25 |
Institutional & Insider Ownership
6.0% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 49.8% of Ontrak shares are owned by institutional investors. 2.2% of Lisata Therapeutics shares are owned by insiders. Comparatively, 46.6% of Ontrak shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings and target prices for Lisata Therapeutics and Ontrak, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lisata Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
| Ontrak | 0 | 0 | 0 | 0 | N/A |
Lisata Therapeutics currently has a consensus price target of $15.00, suggesting a potential upside of 312.09%. Ontrak has a consensus price target of $2.27, suggesting a potential upside of 171.46%. Given Lisata Therapeutics' higher possible upside, equities research analysts clearly believe Lisata Therapeutics is more favorable than Ontrak.
Risk and Volatility
Lisata Therapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, Ontrak has a beta of 2.16, meaning that its stock price is 116% more volatile than the S&P 500.
About Lisata Therapeutics
(Get Rating)
Lisata Therapeutics, Inc. develops biopharmaceuticals. It is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. It is designed to modify the tumor microenvironment by activating a novel uptake pathway that allows anti-cancer drugs to penetrate solid tumors more effectively. The company is headquartered in Basking Ridge, NJ.
About Ontrak
(Get Rating)
Ontrak, Inc. engages in the provision of data analytics based behavioral health management and integrated treatment services to health plans. It offers services through its Ontrak platform solution, which is designed to improve member health, and at the same time, lower costs to the insurer for underserved populations where behavioral health conditions cause or exacerbate co-existing medical conditions. The company was founded by Terren S. Peizer in February 2003 and is headquartered in Santa Monica, CA.
Receive News & Ratings for Lisata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lisata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.